NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease

draft 9-19-17

Clifford R. Jack, Jr. M.D., David A. Bennett, M.D., Kaj Blennow, M.D., Ph.D., Maria C. Carrillo, Ph.D., Billy Dunn, M.D., Cerise Elliott, Ph.D., Samantha Budd Haeberlein, Ph.D., David M. Holtzman, M.D. William Jagust, M.D., Frank Jessen, M.D., Jason Karlawish, M.D., Enchi Liu, Ph.D., Eliezer Masliah M.D., Jose Luis Molinuevo, M.D., Thomas Montine, M.D., Ph.D., Creighton Phelps, Ph.D., Katherine P. Rankin, Ph.D., Christopher Rowe, M.D., Laurie Ryan, Ph.D., Philip Scheltens, M.D., Eric Siemers, M.D., Nina Silverberg, Ph.D., Heather M. Snyder, Ph.D., Reisa Sperling, M.D.

Abstract
In 2011 the National Institute on Aging and Alzheimer’s Association (NIA-AA) created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer’s disease. Scientific progress in the interim led to an initiative by the NIA-AA to update and unify the 2011 guidelines. This unifying update is labeled a “research framework”, because its intended use is for observational and interventional research, not routine clinical care. In the NIA AA research framework Alzheimer’s disease (AD) is defined by its underlying pathologic processes which can be documented by post-mortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e. symptoms/signs) in this research framework which shifts the diagnosis of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β-amyloid deposition, pathologic tau, and neurodegeneration. Two cognitive staging schemes are described: a scheme employing 3 traditional syndromal categories and a 6 stage numeric scheme. We envision that defining AD as a biological construct will enable a more accurate characterization
and understanding of the sequence of events that lead to cognitive impairment as well as the multi factorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people. Importantly, the validity of this construct should be determined in more diverse populations.
1. Preamble

Alzheimer’s disease (AD) was initially defined as a clinico-pathologic entity which was diagnosed definitely at autopsy and in life as possible or probable AD. Over time, however, the distinction between neuropathologic change and clinical symptoms has become blurred. Consequently the term AD is often used to describe two very different entities: a prototypical clinical syndrome without neuropathologic verification, or AD neuropathologic changes. However, a syndrome is not an etiology but rather a clinical consequence of one or more diseases. A biological rather than a syndromal definition of AD is a logical step toward greater understanding of the mechanisms underlying its clinical expression. Disease modifying interventions must engage biologically defined targets and the dementia syndrome does not denote a specific biological target(s). In addition, the most rational framework with which to discover interventions that prevent or delay the initial onset of symptoms is a biologically based definition of the disease that encompasses both the clinical and the preclinical phases. This will advance the public health. Thus a framework suitable for interventional trials should be founded on a biologically based definition of AD and the framework should be harmonized between interventional and observational research.

Neuropathologic examination is the standard for defining AD and there are validated biomarkers that are proxies for AD neuropathologic change. We propose a research framework grounded on a biomarker based definition of AD in living people. In many situations, however, biomarker characterization of research participants is not possible. Research without biomarkers has and will continue to constitute a vital part of our efforts to understand the dementia and MCI syndromes. The presence of a biologically based research framework does not devalue research without biomarkers; the two approaches are complimentary. Also, this framework does not limit but rather enhances research into broadly defined dementia by providing a biologically based definition of one cause of dementia - AD.

The AD field is fortunate that biomarkers of important categories of neuropathologic change, i.e. β-amyloid deposition, pathologic tau, and neurodegeneration, have been and are being developed. This framework is focused on characterizing research participants with these biomarkers. AD biomarker characterization will identify some research participants who have no AD biomarker abnormalities as well as some who likely have diseases other than AD. This research framework does not ignore these individuals but rather provides a system for
characterizing them alongside individuals who are in the Alzheimer’s continuum. The framework is also expandable to incorporate new biomarkers.

2. Background: Rationale for updating 2011 NIA-AA guidelines for Alzheimer’s disease

In 2011 the National Institute on Aging and Alzheimer’s Association (NIA-AA) created separate sets of diagnostic guidelines for the symptomatic or “clinical” stages of Alzheimer’s disease (AD) which were mild cognitive impairment (MCI) and dementia. Recommendations were also created for a stage of AD in individuals without overt symptoms, called “preclinical AD”. The criteria for the symptomatic stages were intended, in part, to aid clinicians in diagnostic decision making, and in part to provide researchers a common framework to define these clinical stages. The recommendations for preclinical AD were not designed for routine clinical care but rather to provide researchers a common language to identify and stage research participants who were not cognitively impaired but had abnormal AD biomarkers. The framework described in this document has that same intention – to give researchers a common language.

Since the publication of the 2011 guidelines, data has continued to accumulate indicating that the cognitive decline in AD occurs continuously over a long period, and that progression of biomarker measures is also a continuous process that begins prior to symptoms. Thus the disease is regarded to be a continuum rather than 3 distinct clinically defined entities. This concept was already recognized but was not formalized in the 2011 NIA AA guidelines.

A common theme in the 2011 recommendations was the use of imaging and cerebrospinal fluid (CSF) biomarkers. In symptomatic individuals, biomarkers were used to refine confidence that AD pathologic changes contributed to a person’s cognitive impairments. In the case of pre-clinical AD, biomarkers were used to define the construct. In the 2011 recommendations, biomarker evidence of cerebral \(\beta\)-amyloidosis in the absence of cognitive symptoms was proposed as sufficient to diagnose preclinical AD. While amyloid biomarkers were placed at the apex of the biomarker hierarchy preclinically, all AD biomarkers, including those reflecting neurodegeneration, were placed on equal footing in the MCI and dementia guidelines. While this discrepancy was noted at the time, there is now a consensus that...
application of biomarkers should be harmonized conceptually across the disease continuum and that biomarkers of neurodegeneration are not equivalent to those reflecting amyloid and pathologic tau accumulation. A major motivation for updating the 2011 guidelines has been the evolution in thinking about biomarkers. Studies published since 2011 have reinforced the idea that certain imaging and CSF biomarkers are valid proxies for neuropathologic changes of AD. Imaging-to-autopsy comparison studies have established that amyloid PET imaging is a valid in vivo surrogate for β-amyloid deposits (in brain parenchyma or vessel walls). It is also now widely accepted that CSF Aβ42 (or the Aβ42/40 ratio) is a valid indicator of the abnormal pathologic state associated with cerebral β-amyloid deposition. An additional development has been the introduction of PET ligands for pathologic tau. By contrast, additional research has highlighted the fact that measures of neurodegeneration or neuronal injury that are commonly used in AD research - MRI, FDG PET, and CSF total tau (T-tau) - are not specific for AD but rather are nonspecific indicators of damage that may derive from a variety of etiologies. Based on this background, NIA-AA leadership formed a work group whose charge was to examine the 2011 guidelines in the context of current scientific knowledge and if appropriate update them. Members of the workgroup were selected by NIA-AA leadership with the goals of providing a range of scientific expertise, broad representation of different institutions and professional organizations involved with AD research, and gender and geographic diversity (including both within the US and international scientists).

3. Guiding principles for updating NIA-AA guidelines for AD

The charge to the 2018 NIA-AA work group was to unify and update the 2011 recommendations in a manner that is consistent with current understanding of the AD continuum. The work group approached this mandate with several guiding principles. First, the overall objective was to create a scheme for defining and staging the disease across its entire spectrum. Experience with the 2011 NIA AA recommendations has shown that a common framework for defining and staging the disease facilitates standardized reporting of research findings across the field.
Second, we determined that these recommendations should be cast as a “research framework”; not as diagnostic criteria or guidelines. Unlike the 2011 NIA-AA criteria for MCI or AD dementia based on clinical criteria (i.e. without biomarkers)\textsuperscript{1,2}, the 2018 research framework is not intended for general clinical practice. It is called a “research framework” because it needs to be validated and modified if needed before being adopted into general clinical practice. There are two categories of studies that will achieve this: longitudinal cohort studies and randomized placebo controlled trials. Cohort studies, particularly community and population based cohorts, will examine the extent to which temporal relationships and patterns of signs, symptoms and biomarkers expected by this framework align with what is observed. These results will support convergent and divergent validity. Trials showing that an intervention modifies both biomarkers and signs and symptoms will establish criterion validity (i.e. a disease modifying effect). Other areas of medicine have used this approach to define pathologic processes using biomarkers, for example, bone mineral density, hypertension, hyperlipidemia and diabetes are defined by biomarkers. Interventions on these biomarkers have been shown to reduce the likelihood of developing fractures, myocardial and cerebral infarctions\textsuperscript{45,46}.

Third, the committee recognized the research framework must function in two major applications – observational cohort studies and interventional trials.

The committee took a step wise approach to creating the 2018 research framework by posing a series of questions where each incremental step built on earlier conclusions.

4. The term “Alzheimer’s disease” refers to an aggregate of neuropathologic changes and thus is defined \textit{in vivo} by biomarkers and by post mortem examination, not by clinical symptoms

We approached the definition of Alzheimer’s disease with awareness of the distinction between a syndrome and a disease. Some will argue that a specific syndrome, i.e. a multi domain amnestic dementia (after other potential etiologies have been excluded), should define AD in living people. Our position, however, is that dementia is not a “disease” but rather is a syndrome composed of signs and symptoms that can be caused by multiple diseases, one of which is AD. As we elaborate in the following paragraph, there are two major problems with using a syndrome to define AD; one, it is neither sensitive nor specific for the neuropathologic changes that define...
the disease, and two, it cannot identify individuals who have the disease but do not (yet) manifest
signs or symptoms \(^{47,48}\). These problems support a definition of disease that advances the public
health goals of a diagnosis that leads to biologically targeted treatment and the ability to
prescribe treatment to prevent or delay disability.

It is now well established that the prototypical multi domain amnestic dementia
phenotype historically used to define AD dementia \(^{49}\) does not rule in AD pathologic change at
autopsy \(^{50-52}\). From 10% to 30% of individuals clinically diagnosed as AD dementia by experts
do not display AD neuropathologic changes at autopsy \(^{50}\) and a similar proportion have normal
amyloid PET or CSF A\(\beta\)42 studies \(^{53-62}\). Thus the multi domain amnestic dementia phenotype is
not specific; it can be the product of other diseases as well as AD \(^{51}\). Non amnestic clinical
presentations, i.e. language, visuospatial, and executive disorders, may also be due to AD \(^{63-66}\).
Thus the prototypical clinical phenotype is not necessarily sensitive for AD neuropathologic
changes. In addition, AD neuropathologic changes are often present without signs or symptoms,
especially in older persons. Thirty to forty percent of cognitively unimpaired elderly persons
have AD neuropathologic changes at autopsy \(^{67,68,69}\) and a similar proportion have abnormal
amyloid biomarkers \(^{32,53-55,60,70-73}\). The fact that an amnestic multi domain dementia is neither
sensitive nor specific for AD neuropathologic change suggests that cognitive symptoms are not
an ideal way to define AD.

The traditional approach to incorporating biomarkers into models of AD began with
patients’ clinical symptoms, which appear late in the disease, and worked backwards to relate
symptoms to biomarker findings. The committee recommends a different approach where the
neuropathologic changes detected by biomarkers define the disease. Defining AD by
neuropathologic change independent from clinical symptoms is a profound shift in thinking. For
many years AD was conceived as a clinical-pathological construct \(^{49}\); it was assumed that if an
individual had typical amnestic multi domain symptoms they would have AD neuropathologic
changes at autopsy and if symptoms were absent they would not have AD at autopsy.

Symptoms/signs defined the presence of the disease in living persons and therefore the concepts
of symptoms and disease became interchangeable. AD later became a clinical-biomarker
construct with International Work Group (IWG) \(^{64,74,75}\) and 2011 NIA-AA guidelines where
biomarkers were used to support a diagnosis of AD in symptomatic individuals, but the
definition of AD was not divorced from clinical symptoms (with the exceptions of the 2011 NIA
AA recommendations on preclinical AD and IWG criteria in autosomal dominate mutation carriers, and NIA AA neuropathologic guidelines).

5. AD biomarkers

Various imaging and CSF biomarkers are widely used in AD and brain aging research. In order to meet the committee’s mandate of arriving at a generalizable research framework, it is helpful to reduce the complexity that results from the variety of available biomarkers. The committee addressed this by following the recommendations from a recent position paper that outlined an unbiased descriptive classification scheme for biomarkers used in AD and brain aging research \(^{15}\). The scheme (which is labeled ATN) recognizes three general groups of biomarkers based on the nature of the pathologic process that each measures ([Table 1]) \(^{15}\). Biomarkers of β-amyloid plaques (labeled “A”) are cortical amyloid PET ligand binding \(^{76,77}\) or low CSF Aβ42 \(^{78-80}\). Biomarkers of fibrillar tau (labeled “T”) are elevated CSF phosphorylated tau (P-tau) and cortical tau PET ligand binding \(^{79,81}\). Biomarkers of neurodegeneration or neuronal injury (labeled “N”) are CSF total tau (T-tau) \(^{82}\), FDG PET hypometabolism and atrophy on MRI \(^{83-89}\).

A limitation of the 2011 NIA-AA recommendations was grouping biomarkers into just 2 categories – amyloid and tau-related neurodegeneration. Tauopathy and neurodegeneration were placed into the same biomarker category. In persons with only AD it is reasonable to assume that neurodegeneration is closely associated with pathologic tau. However, it is increasingly recognized that neurodegeneration/injury, even in classic AD brain regions, also occurs in non-AD conditions. This is particularly so in elderly individuals where co morbidities are common \(^{90}\). ATN classification provides a solution to this problem which is to separate biomarkers that are specific for pathologic tau deposits from those that are nonspecific measures of neurodegeneration/neuronal injury.

The ATN system was designed with both a CSF and an imaging biomarker in each of the 3 biomarker groups ([Table 1]) \(^{15}\). Thus complete ATN biomarker characterization of research participants is possible using either imaging or CSF biomarkers alone. However, some research groups may prefer a mixture of imaging and CSF biomarkers for ATN characterization. For
example when lumbar puncture and MRI are accessible but PET is not, investigators may choose to use CSF Aβ42 and P-tau as the A and T biomarkers and MRI as the N biomarker.

6. Definition of AD

Once the committee agreed that AD should be defined as a biologic construct that is identified by biomarkers in living people, the next logical question was: what biomarker signature or profile(s) defines AD? The committee agreed that only biomarkers that are specific for hallmark AD proteinopathies (i.e. Aβ and pathologic tau) should be considered as potential biomarker definitions of the disease. Different possible biomarker profiles were considered.

Numerous studies have shown that cognitively unimpaired individuals with abnormal amyloid biomarkers have more rapid progression of atrophy, hypometabolism and clinical/cognitive decline than individuals without biomarker evidence of β-amyloid deposition. The proportion of amyloid PET positive clinically normal individuals by age nearly perfectly parallels the (increasing) age specific prevalence of individuals clinically diagnosed as AD dementia 15-20 years later. The first biomarkers to become abnormal in carriers of deterministic AD mutations are those of β-amyloid. These data suggest a causal up-stream role for β-amyloid in the pathogenesis of AD; and while β-amyloidosis alone is insufficient to cause cognitive deterioration directly, it may be sufficient to cause downstream pathologic changes (i.e. tauopathy and neurodegeneration) that ultimately lead to cognitive deterioration. These findings are supported by clinic-pathologic studies as well. Consequently a widely held view is that amyloid biomarkers represent the earliest evidence of AD neuropathologic change currently detectable in living persons. This suggests that abnormal β-amyloidosis biomarkers alone could serve as the defining signature of AD. However, both β-amyloid and paired helical filament (PHF) tau deposits are required to fulfill neuropathologic criteria for AD which suggests that evidence of abnormalities in both β-amyloid and pathologic tau biomarkers should be present in order to apply the label “Alzheimer’s disease” in a living person (Fig 1). With these considerations in mind, the committee agreed on the following definitions.

An individual with biomarker evidence of Aβ deposition alone (abnormal amyloid PET scan or low CSF Aβ 42 or 42/40 ratio) with a normal pathologic tau biomarker would be assigned the label “Alzheimer’s pathologic change” (Table 2) (Fig 2). The term “Alzheimer’s
“disease” would be applied if biomarker evidence of both \( A\beta \) and pathologic tau was present (Fig 1). Alzheimer’s pathologic change and Alzheimer’s disease are not regarded as separate entities but earlier and later phases of the “Alzheimer’s continuum” (an umbrella term that includes both Alzheimer’s pathologic change and Alzheimer’s disease). These definitions are applied independently from clinical symptoms. These definitions meet our specifications to function equally well across the disease spectrum: from early through late life onset, from pre-symptomatic through symptomatic phases, and for typical and atypical clinical presentations.

7. Staging

We next developed a system for staging severity. Our guiding principles were the following. Two types of information about the patient are staged independently from each other: 1) grading disease severity using biomarkers, and 2) grading the severity of cognitive impairment. Measures used to define AD must be specific for the disease while measures used to stage severity need not be. Thus different measures have different roles. \( A\beta \) biomarkers determine whether or not an individual is in the Alzheimer’s continuum. Pathologic tau biomarkers determine if someone who is in the Alzheimer’s continuum has AD, since both \( A\beta \) and tau are required for a neuropathologic diagnosis of the disease. Neurodegenerative/neuronal injury biomarkers and cognitive symptoms, neither of which is specific for AD, are used only to stage severity not to define the presence of the Alzheimer’s continuum.

8. Biomarker profiles and categories

In many research studies it will be most appropriate to treat biomarkers of amyloid, pathologic tau and neurodegeneration/neuronal injury as continuous measures without employing normal/abnormal cut points. However biomarkers used in medicine often use a cut point denoting normal vs abnormal values to support management decisions for an individual patient. The need for discrete categorization of biomarker continua is also obvious for AD clinical trials where hard cutpoints serve as inclusion/exclusion criteria. We recognize from the experience of more mature biomarker defined disease such as cardiovascular disease and osteoporosis that as knowledge of biomarkers and other factors increase, the biomarker...
categorization may change from using cut-points of “normal” or abnormal,” to multi-factorial and multidimensional scoring systems (see for example FRAX criteria for osteoporosis).

The addition of a normal/abnormal cut point for each ATN biomarker group results in 8 different ATN “biomarker profiles” (Table 2): A+T-N-, A+T+N+, etc. Based on the definitions of Alzheimer’s pathologic change and AD outlined earlier, the ATN biomarker system with cut points assigns every individual one of three “biomarker categories” (Table 2): 1) individuals with normal AD biomarkers; 2) those in the Alzheimer’s continuum (subdivided into Alzheimer’s pathologic change and AD); and, 3) those with a normal amyloid biomarker but with abnormal T or N, or both. This latter biomarker profile implies evidence of one or more neuropathologic processes other than AD 102 and has been labeled “suspected non Alzheimer’s pathophysiology” (SNAP) 37.

It is worthwhile re-emphasizing that, like the 2012 NIA-AA classification system for AD neuropathic change 100,101, ATN scoring of biomarkers is independent from clinical symptoms.

The rate of cognitive decline is significantly greater for cognitively impaired and unimpaired individuals who have abnormalities in both an amyloid biomarker and a second biomarker type which could be CSF tau (T- tau or P- tau), atrophy or hypo metabolism in comparison to individuals who have neither or only one of these biomarker abnormalities 29-34,38,39,41-44. These data firmly establish that more advanced disease defined by biomarkers predicts more rapid cognitive decline. Thus a solid evidence base exists proving that combinations of biomarker abnormalities are useful for staging the Alzheimer’s continuum.

While the term stage is more familiar, we use the term “biomarker profile” (Table 2) because the term stage implies a sequence – i.e. stage 1 always precedes stage 2, etc. Many in the field are convinced that amyloidosis induces or facilitates the spread of pathologic tau, and that tauopathy in turn is a proximate cause of neurodegeneration. If so then the logical biomarker sequence of AD would be: A+T-N- then A+T+N- then A+T+N+. It is not certain though where the A+T-N+ profile would fit in a sequential staging scheme. A likely possibility is that A+T-N+ represents evidence of comorbidity – i.e. A+T- represents Alzheimer’s pathologic change while N+ represents evidence of non-AD neurodegeneration/neuronal injury 104 (see Fig 3). Biomarker-autopsy studies are needed to clarify this. We can, however, be confident that A+T-N- represents an early neuropathologic stage while A+T+N+ represents the most advanced. Staging disease severity is thus accomplished by combining binary information from each of the
3 biomarker groups; the more biomarker groups that are abnormal, the more advanced the pathologic stage\textsuperscript{103}.

8.1 Alternatives to binary biomarker groups: Given that Alzheimer’s pathologic change and AD are defined by biomarkers, a single cut point is needed in many situations. However, as pointed out in the ATN position paper\textsuperscript{15}, other options are possible. In many research situations biomarkers are best treated as continuous variables. For example, the risk of short term cognitive decline increases continuously with worsening N biomarkers and this may be true of T biomarkers as well\textsuperscript{105,106}.

Situations can be also envisioned where a three range (2 cut points) approach might be useful\textsuperscript{15,107}. If these 3 ranges were labeled, clearly normal (0), intermediate range (1), clearly abnormal (2), then a 2 cut point biomarker profile might look like $A^2T^1N^0$, etc. Designating an intermediate range using 2 cut points has evolved in other diseases for clinical care, for example, pre hypertension and pre-diabetes have proved to be useful constructs in medicine.

8.2 Personalized medicine: The ATN system moves AD research in the direction of personalized medicine by coding pathologic change in three categories for each research participant and allows for future flexibility by adding other biomarkers as they are discovered and validated. This level of granularity in biomarker classification, perhaps combined with genetic and clinical information, will presumably be useful in tailoring treatment to the individual when various treatments become available.

9. Characteristics and limitations of biomarkers

9.1 CSF vs imaging biomarkers: While we place imaging and CSF biomarkers into common groups a fundamental difference between the two should be recognized. CSF biomarkers are measures of the concentrations of proteins in CSF from the lumbar sac that reflect the rates of both production (protein expression or release/secretion from neurons or other brain cells) and clearance (degradation or removal) at a given point in time\textsuperscript{108,109}. Imaging measures, on the other hand, represent the magnitude of the neuropathologic load or damage accumulated over time. Low CSF Aβ42 is therefore best considered a biomarker of a pathologic state that is associated with amyloid plaque formation and not a measure of amyloid plaque load as amyloid
PET is. Similarly, CSF P-tau is best considered a biomarker of a *pathologic state* that is associated with PHF tau formation and not a measure of pathologic tau deposits as tau PET is.

Discordances between imaging and CSF biomarkers may occur\(^{35,40,110-113}\). In some situations discordance in normal/abnormal labels between an imaging and CSF biomarker within a study is simply a product of how cut points were established that can be rectified by adjusting cut points. The continuous relationship between CSF A\(\beta\)42 and amyloid PET, however, is “L-shaped” rather than linear\(^{110,111,114}\). This may be due to a temporal off set between these 2 measures\(^{115-117}\). In the limited data currently available, tau PET ligand binding is linearly correlated with elevated CSF P tau\(^{109,118,119}\), however, the correlation is imperfect. Given these observations one might ask how could a CSF and an imaging measure be used as biomarkers of a common pathologic process – e.g. amyloidosis, pathologic tau or neurodegeneration/neuronal injury? The answer lies in the chronic nature of AD which spans years- to-decades. Thus an ongoing active pathologic state, denoted by CSF, and the accumulation of neuropathologic load, denoted by imaging, will agree over the long term.

9.2 *Tau PET*: Tau PET is a new modality and the ligands that have been evaluated to date are considered first generation compounds. These compounds suffer from some limitation, the most common being off target binding. However, at least one first generation ligand has emerged as a legitimate biomarker of 3R/4R PHF tau deposits\(^{27}\). Autoradiographic studies have shown that the most widely studied ligand, Flortaucipir (formerly T807 and AV1451), does not bind to amyloid plaques, TDP43, argyrophillic grains or alpha synuclein. AV1451 binds weakly or not at all to sole 4R or sole 3R tau deposits in primary tauopathies\(^{120-122}\). *In vivo* imaging to autopsy comparisons also indicate specific binding of AV1451 to PHF tangles\(^{22}\). Elevated tau PET binding in both medial temporal structures and neocortex is strongly associated with positive amyloid PET scans and with clinical impairment across the normal aging to dementia clinical spectrum\(^{119,123-129}\). High ligand binding predicts future clinical worsening\(^{130,131}\). Longitudinal accumulation correlates with concurrent clinical decline\(^{131}\). New tau PET ligands are in the early stages of development and there is optimism that some of the limitations of the first generation compounds will be addressed in the next generation of tau PET ligands.
9.3 CSF T tau and P tau: The most thoroughly examined P-tau epitope as a CSF biomarker for AD is Threonine 181 (P-tau181)\(^\text{132}\), but other assays for the concentration of P-tau231 and P-tau199 correlate tightly with P-tau181 and show very similar diagnostic accuracy\(^\text{133}\). CSF levels of T-tau and P-tau are tightly correlated within cohorts of AD patients and controls\(^\text{134}\), and the correlation between CSF T tau and P tau is typically much higher than between CSF T tau and MRI or FDG PET\(^\text{35,109}\). Therefore it is reasonable to ask why not place both CSF T tau and P tau in the pathologic tau biomarker group? The answer lies in the divergent behavior of these two measures in other diseases. There is a marked temporary increase in T-tau, with no change in P tau, in traumatic brain injury and stroke that correlates with the severity of neuronal damage\(^\text{135,136}\). It is difficult to rationalize how changes in T tau in such patients can be attributed to brain PHF tau deposition. Further, in Creutzfeldt-Jakob disease, a disorder characterized by very rapid neurodegeneration but not PHF tau accumulation, there is a very marked increase in CSF T-tau (10-20 times more than in AD), while P-tau shows no or minor change\(^\text{137,138}\). The only disorder that consistently shows an increase in CSF P-tau is AD\(^\text{132}\), while this biomarker is normal in other neurodegenerative disorders. The level of CSF Ptau also does correlate with severity of PHF tau accumulation post-mortem\(^\text{81,139}\). Taken together these data indicate that CSF T-tau reflects the intensity of neuronal damage at a specific point\(^\text{108}\) while elevated CSF P-tau reflects an abnormal pathologic state associated with PHF tau formation.

9.4 Biomarkers of neurodegeneration or neuronal injury: Biomarkers in the N category (Table 1) are indicators of neurodegeneration or neuronal injury from many causes; they are not specific for neuronal damage due to AD. In any individual the proportion of observed neurodegeneration/injury that can be attributed to AD vs other possible co morbid conditions (most of which have no extant biomarker) is unknown. This is a recognized limitation of this category of biomarkers. However, the combination of an abnormal MRI, CSF T tau, or FDG PET study with an abnormal amyloid biomarker provides much more powerful prediction of future cognitive decline\(^\text{29-34,38,39,41-44}\) than an abnormal amyloid study alone. This is logical given that neurodegeneration particularly synapse loss is the aspect of AD neuropathologic change that correlates most closely with symptoms\(^\text{140}\). Thus the neurodegeneration / neuronal injury biomarker group provides important pathologic staging information and for this reason it seems inadvisable to eliminate this class of biomarkers from the AD research framework.
It is important to note some differences among biomarkers in the N group. Atrophy on MR likely reflects cumulative loss and shrinkage of the neuropil. CSF T tau likely indicates the intensity of neuronal injury at a given point in time. FDG PET likely indicates both cumulative loss of the neuropil and functional impairment of neurons. These differences may result in discordances.

9.5 Limitations: None of the biomarkers are as sensitive as direct examination of tissue at autopsy. Absolute sensitivity of amyloid PET relative to an autopsy gold standard has been assessed. Typical cut points used for 18F amyloid PET ligands roughly label individuals with none to sparse neuritic plaques normal and individuals with moderate to high neuritic plaque load and Thal phase 4-5 abnormal. A typical cut point used for 11C PIB approximately labels individuals with Thal phase 0-1 normal and individuals with Thal phase 2-5 abnormal. Thus, a negative amyloid PET should not be equated with the complete absence of β-amyloid in the brain or even with absent sparse neuritic plaques. Clinico-pathologic studies suggest that low levels of pathologic changes are associated with subtle cognitive deficits among cognitively unimpaired persons. The amount of pathologic tau that can be present in the brain below the in vivo tau PET detectable threshold is unknown at this time. This limitation is important to bear in mind when considering the distinction between Alzheimer’s pathologic change and AD which hinges on in vivo detection of pathologic tau deposits; however, neither CSF P tau nor tau PET are expected to identify minimal neurofibrillary changes that are detectable by neuropathologic examination. Similarly, the number of neurons or neuronal processes that must be lost in order to detect atrophy on MRI or hypometabolism on FDG PET is not known. For every biomarker there must be an in vivo limit of detection. For this reason we use the terms normal/abnormal for biomarkers rather than positive/negative. Normal/abnormal implies that the test detects what it is capable of within acknowledged limits, and is not an absolute measure of neuropathologic changes in the brain.

The 2018 research framework is designed around biomarker technology that is presently available rather than what would be ideal. ATN biomarkers are available in many research settings at the present time. Other proteintopathies, e.g. α-synuclein and TDP43, are associated with AD pathogenesis or frequently co-occur with AD pathologic changes; however,
validated biomarkers are not presently available for these. Likewise, micro infarcts, hippocampal sclerosis and agyrophillic grains are commonly observed in the brains of the elderly but no reliable markers exist for these either. The ATN biomarker scheme is expandable to incorporate new biomarkers. For example, a vascular biomarker group could be added, i.e. ATNV, when a notion of what constitutes V+ is developed. And, when biomarkers for TDP and α--synuclein are developed, ATN can be expanded to incorporate these as well. An important pathologic process in AD is activation of the innate immune system with both astrocystosis and microgliosis \(^{151}\). This process is involved in the risk and progression of AD. There are not yet reliable markers of these changes though some are emerging \(^{152,153}\). CSF neurogranin is presumed to measure synaptic degeneration and loss \(^{154,155}\) and neurofilament light chain \(^{156}\) to measure axonal injury. When they have been more thoroughly studied, these measures should serve as biomarkers of damage to the neuropil in the “N” group of biomarkers.

9.6 Biomarkers other than ATN: While we focus on biomarkers of AD we emphasize that other biomarkers have a valuable role to play. MRI provides useful information about cerebro vascular disease. Although a biomarker for alpha-synuclein does not yet exist, decreased striatal dopamine transporter uptake of \(^{123}\)I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (\(^{123}\)I-FP-CIT) single photon emission computed tomography (DAT scan) is thought to reflect nigrostriatal degeneration in Lewy body disease \(^{157}\). Likewise, the FDG PET cingulate island sign is often present in Lewy body disease \(^{158}\). These tests may provide useful information about non AD pathologic processes and may be used alone or concordantly with ATN biomarkers to provide a more complete picture of the heterogeneous etiologic nature of dementia. For example, in an individual with an A+T-N+ biomarker profile and a hemispheric infarction(s), atrophy is attributable at least in part to vascular brain injury.

The fact that most dementia is multi factorial presents a challenge both for diagnosis and treatment. It is highly likely that in individuals with multiple brain neuropathologic processes each makes some contribution to the individual’s cognitive impairment. However, the fact that biomarkers of all causes of dementia do not exist at present should not prevent investigators from studying the disease for which a useful suite of biomarkers does exist – AD. In an individual with multiple neuropathologic processes, treating one of them (i.e. AD) should have a beneficial
effect. Therefore using biomarkers to aid in discovery of treatments for AD should not be delayed until biomarkers of all possible etiologies for dementia have been developed.

10. Cognitive staging

Like biomarkers, cognitive performance exists on a continuum. An obvious approach to cognitive staging therefore is to use continuous instruments. Continuous cognitive measures may be the preferred outcome measure in many modern clinical trials. The committee felt it was also appropriate to outline categorical cognitive staging schemes. In the 2011 NIA-AA guidelines cognitive staging was implicit rather than explicit. Three different documents were published describing preclinical AD, MCI, and dementia; however, these categories have at times been interpreted to indicate three distinct entities. In 2018 we avoid the notion of separate entities, and instead use the terminology staging the cognitive continuum.

One of the specifications of the NIA AA research framework was that it be applicable in two distinct research contexts – interventional trials and observational research. In many if not most modern AD interventional trials, individuals are selected for inclusion with the aid of biomarkers. The studies are concerned only with a defined portion of the population – those in the Alzheimer’s continuum. For observational research on the other hand the research questions often require that all members of a recruited sample are included (those with non-AD pathologic changes, normal AD biomarkers, and those in the Alzheimer’s continuum). In these studies research questions often hinge on the presence of heterogeneity within the cohort – which is screened out of AD trial cohorts. We therefore outline 2 types of categorical clinical staging schemes. The first is syndromal categorical cognitive staging which employs traditional syndromal categories and is applicable to all members of a recruited cohort (i.e. includes all biomarker profiles). The second is a numeric clinical staging scheme that is applicable only to those in the Alzheimer’s continuum.

The committee also recognized that cognitive staging had to function both when prior longitudinal clinical or cognitive testing evaluations were available for participants, or when prior information is unavailable and the participant is being evaluated for the first time.
10.1 Syndromal categorical cognitive staging: The syndromal cognitive staging scheme divides the cognitive continuum into 3 traditional categories – Cognitively Unimpaired (CU), MCI, and dementia with dementia further subdivided into mild, moderate and severe (Table 3). This 3-category division serves as the basis for cognitive categorization in many large ongoing studies. Many in the research community feel that it has been and continues to be effective for clinical research and that abandoning it would unnecessarily disrupt ongoing studies. Dividing the cognitive continuum into these 3 syndromal categories also has been adopted by many medical practitioners. It has also been codified for clinical practice in the DSM 5 criteria by the mild cognitive disorder (essentially MCI) and major cognitive disorder (essentially dementia) labels.

While the definitions of CU, MCI and dementia (Table 3) are largely the same as in the 2011 NIA AA guidelines there are differences. For example the 2011 guidelines included only those cognitively unimpaired individuals who had an abnormal amyloid biomarker study (i.e. preclinical AD). In contrast in the NIA AA research framework the definition of CU is independent from biomarker findings. In the 2011 guidelines for MCI, the diagnosis was based on clinical judgment when all available information about the patient was considered. In the NIA AA research framework the diagnosis can be based on clinical judgment and/or on cognitive test performance. In the 2011 guidelines an amnestic multi domain dementia was labeled “probable or possible AD by clinical criteria” without requiring biomarker documentation of AD. In the NIA AA research framework the labels CU, MCI and dementia denote only severity of cognitive impairment and are not used to infer its etiology.

**Nomenclature:** Every individual will have both a biomarker profile and a cognitive stage. Many researchers indicated a preference to retain traditional descriptive terms from 2011 that combined these two sources of information. In Table 4 we illustrate descriptive terminology combining biomarker profile and a cognitive stage which retains nomenclature from 2011 but does depart from 2011 naming in some ways. For example the label “Alzheimer’s disease with MCI (2018)” is used rather than “MCI due to Alzheimer’s disease (2011)”. By this we indicate that although the person has an AD biomarker profile, we cannot know if their cognitive deficit is attributable to AD alone or in addition to other potential comorbidities. In Table 4 we further recognize contributions of co morbidities for individuals with an A+T-N+ biomarker profile with
the descriptive phrase “Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change”. By this we imply that in an A+T-N+ MCI individual both Alzheimer’s and non-Alzheimer’s pathologic change may be contributing to the individual’s impairment. The NIA AA framework naming convention places the biomarker category in the lead position. In addition to carrying forward NIA AA 2011 terminology we also incorporate the term “prodromal AD” from the IWG which many investigators find useful (Table 4).

An alternative approach to descriptive names is to simply combine ATN biomarker profile with cognitive stage without using descriptive phrases; that is, combine the row and column names from Table 4 without the descriptive phrases in the body of the table; for example, “A+T+N+ dementia” instead of “Alzheimer’s disease with dementia”. Some groups may prefer this “row and column” naming approach.

Table 4 illustrates the principle that biomarker profile and cognitive staging represent independent sources of information. For a given cognitive stage (i.e. a given column in Table 4) every biomarker profile will be present in the population. Likewise different cognitive stages may be present in the population among people with the same biomarker profile (i.e. a given row in Table 4). Many effects can blur the relationship between neuropathologic severity and cognitive symptoms at the individual level. These include protective factors, such as cognitive reserve \(^{165-167}\), as well as risk factors, such as co morbid pathologic processes \(^{168,169,170}\).

Table 5 illustrates the principle that biomarker profiles within the Alzheimer’s continuum raise or lower the risk of short term cognitive decline; and that cognitive stage provides additional independent information about the risk of future cognitive decline.

10.2 Numeric clinical staging: The committee also created a “numeric clinical staging scheme” (Table 6) that avoided traditional syndromal labels and is specific for only those in the Alzheimer’s continuum. This staging scheme reflects the sequential evolution of AD from an initial stage characterized by the appearance of abnormal AD biomarkers in asymptomatic individuals. As biomarker abnormalities progress the earliest subtle symptoms become detectable. Further progression of biomarker abnormalities is accompanied by progressive worsening of cognitive symptoms culminating in dementia. A common application for this
numeric cognitive staging scheme would be interventional trials since it is applicable only to individuals who are in the Alzheimer’s continuum.

It is apparent that numeric stages 1-6 (Table 6) bear a close resemblance to the global deterioration scale with the important distinction that the global deterioration scale was created in the pre biomarker era. Stage 1 (Table 6) is defined by biomarker evidence of the Alzheimer’s continuum in asymptomatic individuals. Stage 2 describes the earliest detectable clinical consequence of the Alzheimer’s continuum and is similar to “stage 3 preclinical AD” in the 2011 NIA AA guidelines. Stage 3 describes cognitive impairment that is not severe enough to result in significant functional loss. Stages 4-6 describe progressively worse functional loss.

The nature of decline or impairment in stages 2 - 6 may involve any cognitive domain(s) – not only memory. We suspect that finding individuals in stages 3-6 with an A+T-N- profile will be uncommon, as clinical symptoms are typically associated with evidence of neuronal injury. We also suspect that A+T-N+ biomarker profiles in symptomatic individuals may be due to the combination of Alzheimer’s and non Alzheimer’s pathologic change. However, both of these biomarker profiles are included in all 6 numeric stages for research purposes.

The syndromal categories in Table 3 and numeric stages in Table 6 obviously point to similar constructs. A cognitively unimpaired individual who also has no subjective or objective evidence of subtle decline (Table 3) and Stage 1 (Table 6) both describe an asymptomatic state. A cognitively unimpaired individual who has subjective or objective evidence of subtle decline (Table 3) is similar to Stage 2 (Table 6). MCI (Table 3) and Stage 3 (Table 6) both describe cognitive impairment short of dementia. Mild, moderate and severe dementia (Table 3) is identical to stages 4-6 (Table 6).

However, since the two staging systems address different needs there are important differences between them. First, numeric staging is only applicable to those in the Alzheimer’s continuum while syndromal categorical staging includes all biomarker profiles. Second, stage 2 is called out as a distinct transitional stage between asymptomatic (stage 1) and mildly impaired (stage 3) in the numeric scheme (table 6) but there is no separate category between clinically unimpaired and MCI in the syndromal categorical scheme. Our reasoning was that if an individual is in the Alzheimer’s continuum, then it is reasonable to label subjective complaints or evidence of subtle cognitive decline as a transitional stage attributable to the pathologic process. However, in the syndromal categorical scheme (table 3) where abnormal biomarkers are not
required, it is not reasonable to assume that subjective complaints (which are very common in aging) represent a symptom of any specific disease(s). Third, neurobehavioral symptoms are treated differently between the two staging systems. While cognitive symptoms represent the core clinical feature of AD, in some individuals the initial presentation may be neurobehavioral (e.g. depression, anxiety, apathy) rather than cognitive \( ^{172} \). Therefore in the numeric scheme an individual may be placed into stage 2 on the basis of neurobehavioral symptoms alone – i.e. without evident cognitive decline. To reflect this we use the term “clinical staging” rather than cognitive staging to recognize that early clinical manifestations of AD may be either cognitive or neurobehavioral. Individuals must have cognitive impairment to be placed into numeric stages 3 - 6 \( ^{173} \). We recognize though that neurobehavioral symptoms often do not have a neurodegenerative etiology. Thus, our position is that without biomarker abnormalities indicating the presence of a neurodegenerative disease, it is not reasonable to classify patients with isolated neurobehavioral symptoms as having MCI or dementia. Consequently, cognitive symptoms are required for inclusion in these categories in the syndromal staging scheme which is not limited to individuals in the Alzheimer’s continuum.

Because only 4 biomarker profiles are eligible for numeric staging, the committee saw an opportunity to streamline nomenclature. In this shorthand naming scheme the four Alzheimer’s continuum biomarker profiles are labeled a-d:

a) A+T-N-
b) A+T-N+
c) A+T+N-
d) A+T+N+

Thus, individuals can be fully described by a single number/letter combination denoting numeric clinical stage and biomarker profile- i.e. stage 1a, stage 2c, etc.

11. Implementation

The committee avoided making specific recommendations for many implementation details. Our objective was to outline a general research framework that could be adapted by individual research groups to their own research goals and environment. For example, different research groups will employ the cognitive testing battery and cut points that best fit their own research samples.
Evaluation of images may be by visual interpretation or by quantitative methods. Methods of image quantification vary among research groups and are constantly being refined. For tau PET, FDG and MRI the locations of the abnormalities are closely related to symptoms and thus quantification methods should be sensitive to location \(^{174}\). This is not the case for amyloid PET, however, where ligand uptake appears diffusely throughout the cortex and its topography is not directly related to symptoms \(^{63,175}\). Cut points must be determined and age norming biomarker cut points is controversial. Arguments have been made that neurodegenerative biomarkers should be age normed because loss of neuropil is closely tied with ageing. By contrast a strong argument can be made that any amyloid or pathologic tau detected by a biomarker is abnormal regardless of age and thus age norming biomarker cutpoints is inappropriate. The distinction between normal aging and age related disease has been debated for decades and we do not presume to settle this here. This is ultimately a matter of selecting the definitions that best serve the goal of those definitions.

Initiatives to standardize imaging and CSF biomarker measures exist, e.g., the Centiloid Project \(^{176}\), EADC-ADNI Harmonized Protocol for hippocampal segmentation \(^{177}\), Alzheimer’s Association Global Biomarkers Standardization Consortium \(^{178}\) and International Federation of Clinical Chemistry Working Group for CSF proteins \(^{179}\). These efforts are the subject of ongoing research but universal standards have not yet been established \(^{180}\). For amyloid imaging, where over a decade of data are available, different ligands, methods of image acquisition, and image processing can result in different thresholds when compared to neuropathologic standards \(^{20,21,181}\). These issues are currently less understood for pathologic tau imaging, but the questions are equally tractable. The committee avoided taking a proscriptive approach to these methodologic issues with the assumption that this was best left to expert work groups and individual research centers.

12. Genetics

Genetics is not formally included in the research framework because our concept of disease rests on neuropathologic change (that can be detected by biomarkers). In contrast genic variants do not measure pathologic change but rather indicate an individual’s risk for developing pathologic change. For example, inheritance of an \(APOE\) \(\varepsilon4\) allele neither defines the presence of Alzheimer’s pathologic change or AD, nor does it indicate any particular stage of the disease.
The penetrance of the classic autosomal dominate mutations in APP, PSEN1, or PSEN2, is essentially 100% and for this reason it could be argued that these mutations confer a pathologic state that exists from conception. However, our definitions of AD pathologic change and AD are based on biomarker evidence of disease, and our current biomarkers do not detect pathologic processes in mutation carriers at very young age.

13. Clinical research without biomarkers or with incomplete biomarker information

Although incorporation of biomarkers into clinical research is already widespread and growing, we recognize that in some settings it may not be feasible to obtain biomarkers, such as areas without access to the necessary laboratories and imaging facilities, persons who are reluctant to participate in research studies, or low and middle income countries without adequate financial resources to support biomarker research. In other cases, a study may simply not be able to justify the cost and participant burden, such as large, longitudinal, community-based cohort studies that can tolerate the loss of diagnostic precision more than it can tolerate the bias that will be introduced by modest participation rates in biomarker data collections. Finally, there may be research studies that do not require biomarker evidence of AD to achieve the specific goals of the research program such as studies of non-specific cognitive decline or dementia. Clinical research without biomarkers therefore remains a valuable component of the research landscape that will continue to provide important contributions.

Investigators involved in studies without biomarkers may wish to employ the traditional terms possible or probable AD dementia for research participants who display a prototypical syndrome (although these terms are not employed in the NIA AA research framework). Such studies provide valuable information on the burden of disability. In both the 1984 and in the 2011 NIA AA criteria for AD dementia a probabilistic assumption about AD pathologic changes was inferred from the clinical presentation alone. AD neuropathologic change is documented in 80%, or more of cases with a traditional clinical diagnosis of “AD dementia”. However, 40% or more of cognitively unimpaired individuals over age 80 have AD neuropathologic changes at autopsy or by biomarkers. Thus multi domain amnestic dementia is reasonably good at identifying the presence of AD neuropathologic changes but is incapable of identifying the absence of AD neuropathologic changes. This situation is analogous to inferring cerebral infarction from a clinical diagnosis of stroke which can be made, albeit with
less diagnostic fidelity, in the absence of MRI based solely on a history and neurologic examination. What cannot be done without MRI is make a diagnosis of subclinical or silent stroke which is present in about 25% -30% of older persons. Similarly, without biomarkers one has no information on preclinical AD.

A related issue is that many studies will not have biomarker data for complete ATN characterization of study participants. Because tau PET is relatively new, incomplete biomarker information will occur in studies that use imaging for amyloid and neurodegenerative biomarker characterization but lack tau PET. Participants in these studies may be categorized on the basis of information that is available i.e. A+ places the participant in the “Alzheimer's continuum”, A-N- is normal biomarkers and A-N+ is suspected non-AD pathologic change (Table 2). A second common situation where biomarker data will be incomplete is studies with MRI or FDG PET, but without either PET or CSF molecular biomarkers for amyloid and tau. In this situation, while MRI or FDG PET cannot be used to indicate the Alzheimer's continuum, they can be highly useful as measures of neurodegeneration which in turn is a powerful predictor of future clinical course.

14. Comparison to IWG

In addition to the NIA AA, the other group that has established diagnostic guidelines for AD that incorporate biomarkers is the international work group (IWG). In the most recent formal IWG document, published in 2014, the diagnosis of AD required the presence of cognitive symptoms plus an AD biomarker signature. This could be either an abnormal amyloid PET study or both abnormal CSF Aβ and tau. The NIA-AA research framework aligns with these criteria in recognizing that neither hypometabolism nor atrophy are specific for AD and thus cannot be used to support a diagnosis of AD. One difference though is that we regard CSF T tau as a nonspecific marker of neuronal injury while the IWG 2014 treats the combination of elevated T tau and low Aβ 42 as a biomarker signature that is specific for AD. In addition, tau PET was not available in 2014 and thus was not included in the 2014 IWG criteria. In addition to an AD biomarker signature, cognitive symptoms (specifically either a typical or a known atypical AD phenotype) were also required to diagnose AD in IWG 2014. Individuals with symptoms that fell short of dementia were labeled prodromal AD. Asymptomatic individuals with deterministic autosomal dominant mutations and those with Down’s syndrome were an...
exception and were labeled presymptomatic AD. Cognitively unimpaired individuals with an abnormal amyloid PET study or a CSF study demonstrating both abnormal Ab and tau were labeled “asymptomatic at risk for AD”. The most significant difference between 2014 IWG and the NIA AA reproach framework is that, with the exception of genetically determined AD, the 2014 IWG diagnosis of AD in living persons required both biomarker and clinical findings and therefore was not purely a biological construct.

In a paper on preclinical AD (published in 2016 \textsuperscript{14} that may be considered part of the IWG series), the diagnosis of AD was extended to include asymptomatic individuals with biomarker evidence of both A\textbeta and tau. In contrast to IWG 2014, symptoms were no longer required to reach a diagnosis of AD. Some differences with the NIA AA research framework remain however. Preclinical AD 2016 defines a cognitively unimpaired individual with an abnormal A\textbeta biomarker and normal tau (A+T-) as “at risk for AD, asymptomatic A+” and one with A-T+ as “at risk for AD, asymptomatic T+”. We label the former Alzheimer’s pathologic change and the latter suspected non Alzheimer’s pathologic change (in keeping with the NIA AA pathologic definition of primary age related tauopathy as not Alzheimer’s disease \textsuperscript{100,101}). Importantly, the NIA AA research framework uses “at risk” in a much different connotation, referring to asymptomatic individuals with biomarker evidence of AD as having AD but being “at risk” of subsequent cognitive decline (as opposed to “at risk” for AD). While differences remain, IWG 2016 and the NIA research framework are aligned on the key issue that the combination of an abnormal Ab and tau biomarker constitutes AD regardless of cognitive symptoms and thus AD is a biologically defined entity throughout its continuum. This is an important step toward harmonization.

15. Future directions

The design of this framework poses many readily testable questions, questions that are essential for validating the framework. The degree to which this framework adds value to the AD research field will be determined by this research. Most of the biomarker data to date has been largely been generated from highly educated people of European ancestry and it will be necessary to evaluate this framework in diverse cohorts across a range of ethnic and socio-economic groups \textsuperscript{190}. Similarly, much of the biomarker data to date has been generated from
highly selected clinic samples and evaluation of the framework in population based samples is needed.

PET biomarkers of amyloid\textsuperscript{16-21} or pathologic tau\textsuperscript{120,121} deposition or MRI measures of neurodegeneration/neuronal injury\textsuperscript{141,142} have been convincingly validated using tissue to tissue or image to tissue comparisons. However, CSF biomarkers reflect a complex interaction among many different physiologic rates and validation is more difficult than with imaging. Development of physiologically based methods to validate CSF biomarkers would be extremely helpful.

We recognize that current biomarkers used in AD research are either expensive or invasive. The current generation of biomarkers is invaluable for discovery; however, widespread, routine clinical use will be facilitated by the development of less expensive and invasive biomarkers. For example, new ultrasensitive immunoassay techniques may enable measurement of minute amounts of brain specific proteins in blood samples\textsuperscript{191}. Some candidate blood biomarkers such as neurofilament light protein show promise as non-disease specific tools to identify neurodegeneration\textsuperscript{192}. Plasma β-amyloid measures now show promise as a screening test\textsuperscript{193}. In the future, less invasive/expensive blood-based biomarker tests along with genetics, clinical and demographic information will likely play an important screening role in selecting individuals for more expensive/invasive biomarker testing. This has been the history in other biologically defined diseases such as cardiovascular disease (see for example the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults)\textsuperscript{194}.

The NIA-AA research framework defines the presence and severity of AD by biomarkers and treats cognitive impairment as a symptom/sign of the disease rather than the definition of the disease. This approach should enhance efforts to understand both the biology of AD and the multi factorial etiology of dementia which has been obscured to some extent in the past by equating amnestic multi domain dementia with the presence of AD neuropathologic changes; and, by equating the absence of the prototypical dementia syndrome with the absence of AD neuropathologic changes. This approach can be adopted for other neurodegenerative disorders when specific biomarkers of other proteinopathies (\(\alpha\)-synuclein, TDP43 and 3R or 4R tauopathies) become available.
### Text Box #1 - Glossary

**Alzheimer disease (AD)** – refers to β-amyloid plaques and pathologic tau deposits, defined in vivo by abnormal biomarkers of β-amyloid and pathologic tau (both are required)

**Alzheimer’s pathologic change** – early stage of Alzheimer’s continuum, defined in vivo by an abnormal β-amyloid biomarker with normal pathologic tau biomarker

**Alzheimer’s continuum** – refers to individuals with biomarker designation of either AD or Alzheimer’s pathologic change

**Biomarker group** – refers to three different pathologic processes a biomarker can measure: β-amyloid (A), pathologic tau (T) and neurodegeneration/neuronal injury (N)

**Biomarker profile** – binarizing each of the 3 biomarker groups into normal/abnormal (+/-) results in 8 possible biomarker profiles – e.g. A+T-N-, A+T+N-, etc.

**Biomarker category** – biomarker profiles are grouped into three possible biomarker categories: normal AD biomarkers, A-T-N-; Alzheimer’s continuum, any A+ combination; non Alzheimer’s pathologic change (i.e. SNAP), A-T+N-, A-T-N+, or A-T+N+.

**Cognitively Unimpaired (CU)** – cognitive performance in the non-impaired range for that individual – defined as not MCI or demented

**Neurobehavioral symptoms** – symptoms attributable to mood or behavioral disorders – e.g. anxiety, depression, apathy

**Transitional cognitive decline** – cognitive performance in the non-impaired range but with a subjective complaint of cognitive decline, a subtle decline measured on longitudinal cognitive testing, or both.
The NIA AA research framework builds on but implements a number of changes from the 2011 NIA AA guidelines. In the research framework the term AD refers to pathologic processes and therefore in living persons is defined by biomarkers. Thus, the terms probable and possible AD based on clinical presentation alone are not used. AD is defined as a continuous process in both cognitive and biomarker domains (research framework) rather than as three separate clinical entities (2011). Characterization of pathologic processes by biomarkers is harmonized across the disease continuum in the research framework.

Biomarkers are grouped into those of β-amyloid, pathologic tau, and neurodegeneration or neuronal injury; unlike 2011 where tau and neurodegeneration/neuronal injury biomarkers were placed into the same category. Unlike 2011, biomarker staging includes all members of the population - i.e. individuals in the Alzheimer’s continuum, with non-AD pathologic changes and with normal biomarker profiles. While AD is defined by biomarkers, severity is staged by both biomarkers and cognitive symptoms. The research framework outlines 2 different systems for staging the severity of cognitive symptoms. A syndromal categorical scheme which largely preserves the three clinical categories from 2011 – cognitively unimpaired, MCI and dementia. This is applicable to all members of the population regardless of biomarker profile. A numeric clinical staging scheme that is applicable only to individuals in the Alzheimer’s continuum.
1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. *Alzheimers Dement.* 2011;7(3):263-269.

2. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. *Alzheimers Dement.* 2011;7(3):270-279.

3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):280-292.

4. Jack CR, Jr., Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):257-262.

5. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. *Neurology.* 2010;74(10):807-815.

6. Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis of age-related cognitive decline. *Neurology.* 2010;75(12):1070-1078.

7. Monsell SE, Mock C, Hassenstab J, et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. *Neurology.* 2014;83(5):434-440.

8. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. *The New England journal of medicine.* 2012;367(9):795-804.

9. Benzinger TL, Blazey T, Jack CR, Jr., et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proc Natl Acad Sci U S A.* 2013;110(47):E4502-4509.

10. Fleisher AS, Chen K, Quiroz YT, et al. Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study. *JAMA Neurol.* 2015;72(3):316-324.

11. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *Lancet Neurol.* 2013;12(4):357-367.

12. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann Neurol.* 2011;69(1):181-192.

13. Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. *Sci Transl Med.* 2014;6(226):226ra230.

14. Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement.* 2016;12(3):292-323.

15. Jack CR, Jr., Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology.* 2016;87(5):539-547.

16. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain.* 2008;131(Pt 6):1630-1645.

17. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. *Arch Neurol.* 2011;68(11):1404-1411.

18. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. *Lancet Neurol.* 2012;11(8):669-678.
19. Clark CM, Schneider JA, Bedell BJ, et al. Use of Florbetapir-PET for Imaging B-Amyloid Pathology. *JAMA: The Journal of the American Medical Association.* 2011;305(3):275-283.

20. Murray ME, Lowe VJ, Graff-Radford NR, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. *Brain.* 2015;138(Pt 5):1370-1381.

21. Thal DR, Beach TG, Zanette M, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-beta pathology. *Alzheimers Dement.* 2015;11(8):975-985.

22. Ikonomovic M, Abrahamson E, Kofler J, et al. Neuropathology and biochemical correlations of [F-18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzheimer's disease. Paper presented at: 11th Human Amyloid Imaging; Jan 11-13, 2017; Miami, Florida.

23. Seo SW, Ayakta N, Grinberg LT, et al. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. *Neuroimage Clin.* 2017;13:130-137.

24. Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. *Trends Pharmacol Sci.* 2015;36(5):297-309.

25. Vos SJ, Gordon BA, Su Y, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. *Neurobiol Aging.* 2016;44:1-8.

26. Mormino EC, Papp KV, Rentz DM, et al. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. *JAMA Neurol.* 2016;Epub ahead of print.
37. Jack CR, Jr., Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. *Ann Neurol.* 2012;71(6):765-775.

38. Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. *Ann Neurol.* 2013;74(2):199-208.

39. Wisse LE, Butala N, Das SR, et al. Suspected non-AD pathology in mild cognitive impairment. *Neurol. Aging.* 2015;36(12):3152-3162.

40. Gordon BA, Blazey T, Su Y, et al. Longitudinal beta-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. *JAMA Neurol.* 2016;Epub ahead of print.

41. Wirth M, Villeneuve S, Haase CM, et al. Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. *JAMA Neurol.* 2013;70(12):1512-1519.

42. Toledo JB, Weiner MW, Wolk DA, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. *Acta Neuropathol Commun.* 2014;2(1):26.

43. Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. *Neurology.* 2013;80(11):1048-1056.

44. Vos SJ, Verhey F, Frolich L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. *Brain.* 2015;138(Pt 5):1327-1338.

45. Greene JA. The abnormal and the pathological: Cholesterol, statins, and the threshold of disease. In: Tone A, Siegel Watkins E, eds. *Medicating Modern America: Prescription Drugs in History.* New York New York University Press; 2007:193-228.

46. Karlawish J. Desktop medicine. *JAMA.* 2010;304(18):2061-2062.

47. Sperling RA, Jack CR, Jr., Aisen PS. Testing the right target and right drug at the right stage. *Sci Transl Med.* 2011;3(111):111cm133.

48. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. *Nat Rev Neurol.* 2013;9(1):54-58.

49. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology.* 1984;34(7):939-944.

50. Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. *Acta Neuropathol.* 2011;121(5):571-587.

51. Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. *Ann Neurol.* 2014;75(4):597-601.

52. Barnes LL, Leurgans S, Aggarwal NT, et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. *Neurology.* 2015;85(6):528-534.

53. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. *Neurobiol Aging.* 2010;31(8):1275-1283.

54. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. *Neurology.* 2007;68(20):1718-1725.

55. Jack CR, Jr., Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. *Brain.* 2008;131(Pt 3):665-680.

56. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014;370(4):322-333.

57. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014;370(4):311-321.
947  58. Zwan MD, Bouwman FH, Konijnenberg E, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2.
948  59. Ossenkoppele R, Prins ND, Pijnenburg YA, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9(4):414-421.
949  60. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA. 2015;313(19):1924-1938.
950  61. Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5 Suppl):S72-83.
951  62. Rodrigue KM, Kennedy KM, Devous MD, Sr., et al. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):387-395.
952  63. Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388-401.
953  64. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127.
954  65. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785-796.
955  66. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid pet positivity in dementia syndromes: A meta-analysis. JAMA. 2015;313(19):1939-1949.
956  67. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844.
957  68. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991;12(4):295-312.
958  69. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087-1095.
959  70. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
960  71. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
961  72. Donohue MC, Jacqm-in-Gadda H, Le Goff M, et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014;10(5 Suppl):S400-410.
962  73. van Harten AC, Visser PJ, Pijnenburg YA, et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9(5):481-487.
963  74. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.
964  75. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.
965  76. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
966  77. Villain N, Chetelat G, Grassiot B, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135(Pt 7):2126-2139.
967  78. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a predictor of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.

DO NOT REPRODUCE
79. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393.

80. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619-627.

81. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006;129(Pt 11):3035-3041.

82. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.

83. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1):85-94.

84. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 2001;358(9277):201-205.

85. Besson FL, La Joie R, Doeuvre L, et al. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. J Neurosci. 2015;35(29):10402-10411.

86. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497-510.

87. Knopman DS, Jack CR, Jr., Wiste HJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol. 2013;70(8):1030-1038.

88. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218.

89. Kovacs GG, Milenkovic I, Wohrer A, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126(3):365-384.

90. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol. 2013;74(6):905-913.

91. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40(1):104-114.

92. Skoog I, Davidsson P, Aevvarson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15(3):169-176.

93. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78(5):461-464.
95. Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA. 2017;317(22):2305-2316.

96. Petersen RC, Wiste HJ, Weigand SD, et al. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurol. 2016;73(1):85-92.

97. Papp KV, Rentz DM, Mormino EC, et al. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017;88(15):1431-1438.

98. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378-384.

99. Mortimer JA, Snowdon DA, Markesbery WR. The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord. 2009;23(2):152-157.

100. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11.

101. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1-13.

102. Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86(15):1377-1385.

103. Jack CR, Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.

104. Jack CR, Jr., Wiste HJ, Weigand SD, et al. Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. The Lancet Neurology. 2017.

105. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal Fluid Levels of beta-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Arch Gen Psychiatry. 2012;69(1):98-106.

106. Jack CR, Jr., Wiste HJ, Vemuri P, et al. Brain beta-amyloid measure and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain. 2010;133(11):3336-3348.

107. Klunk WE, Cohen A, Bi W, et al. Why we need two cutoffs for amyloid-imaging: Early versus Alzheimer’s-like amyloid-positivity. Paper presented at: Alzheimer’s Association International Conference2012; Vancouver, British Columbia, Canada.

108. Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. The Lancet Neurol. 2003;2(10):605-613.

109. Gordon BA, Friedrichsen K, Brier M, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139(Pt 8):2249-2260.

110. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74(6):826-836.

111. Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85(14):1240-1249.

112. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-1199.
113. Alexopoulos P, Kriett L, Haller B, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. *Alzheimers Dement.* 2014;10(6):684-689.

114. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann Neurol.* 2006;59(3):512-519.

115. Mattsson N, Insel PS, Donohue M, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. *Brain.* 2015;138(Pt 3):772-783.

116. Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. *Brain.* 2016;139(Pt 4):1226-1236.

117. Vlassenko AG, McCue L, Jasielec MS, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. *Ann Neurol.* 2016;80(3):379-387.

118. Chhatwal JP, Schultz AP, Marshall GA, et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. *Neurology.* 2016;87(9):920-926.

119. Brier MR, Gordon B, Friedrichsen K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. *Sci Transl Med.* 2016;8(338):338ra366-338ra366.

120. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. *Ann Neurol.* 2015;78(5):787-800.

121. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. *Acta Neuropathol Commun.* 2016;4(1):58.

122. Marquie M, Normandin MD, Meltzer AC, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. *Ann Neurol.* 2017;81(1):117-128.

123. Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. *Ann Neurol.* 2016;80(2):247-258.

124. Johnson KA, Shultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer's disease. *Ann Neurol.* 2016;79(1):110-119.

125. Scholl M, Lockhart SN, Schonhaut DR, et al. PET Imaging of tau deposition in the aging human brain. *Neuron.* 2016;89(5):971-982.

126. Lowe V, Wiste HJ, Pandey M, et al. Tau-PET imaging with AV-1451 in Alzheimer's disease. Paper presented at: Human Amyloid Imaging; Jan 14, 2016; Miami Beach, FL.

127. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. *Brain.* 2016;139(Pt 5):1539-1550.

128. Sperling RA, Schultz AP, Rentz DM, et al. The A4 study: Preliminary analyses of baseline tau PET imaging. Paper presented at: 11th Human Amyloid Imaging; Jan 11-13, 2017, 2017; Miami, Florida.

129. Cho H, Choi JY, Lee SH, et al. Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer’s disease. *Neurobiol Aging.* 2017;53:103-111.

130. Devous Sr MD, Navitsky M, Siderowf A, et al. Baseline 18F Flortaucipir SUVR, but not amyloid or cognition, predicts cognitive decline over 18 months in Phase 2 trial subjects. Paper presented at: 11th Human Amyloid Imaging; Jan 11-13, 2017, 2017; Miami, Florida.

131. Hanseeuw B, Becker A, Schultz AP, et al. Longitudinal tau accumulation is associated with cognitive decline in normal elderly. Paper presented at: 11th Human Amyloid Imaging; Jan 11-13, 2017, 2017; Miami, Florida.

132. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. *The Lancet Neurology.* 2016;15(7):673-684.
133. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61(1):95-102.

134. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3):231-245.

135. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297(3):187-190.

136. Ost M, Nylen K, Csajbok L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67(9):1600-1604.

137. Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol. 2014;71(4):476-483.

138. Buerger K, Otto M, Teipel SJ, et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging. 2006;27(1):10-15.

139. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid (beta)-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-389.

140. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572-580.

141. Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience. 2000;95(3):721-725.

142. Zarov C, Vinters HV, Ellis WG, et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol. 2005;57(6):896-903.

143. Barkhof F, Polvikoski TM, van Straaten EC, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology. 2007;69(15):1521-1527.

144. van Rossum IA, Vos SJ, Burns L, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology. 2012;79(17):1809-1816.

145. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80(19):1784-1791.

146. Chetelat G, Ossenkoppele R, Villemagne VL, et al. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain. 2016;139(Pt 9):2528-2539.

147. Roberts BR, Lind M, Wagen A, et al. Biochemically-defined pools of Aβ-amyloid in Alzheimer's disease: correlation with Aβ-PET imaging and a first approximation of accumulation rates of Aβ. Brain. 2017;In press.

148. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72(4):599-609.

149. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62(4):406-413.

150. James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain. 2016.

151. Thambisetty M, An Y, Nalls M, et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry. 2013;73(5):422-428.
152. Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. *Biol Psychiatry.* 2010;68(10):903-912.

153. Piccio L, Deming Y, Del-Aguila JL, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. *Acta Neuropathol.* 2016;131(6):925-933.

154. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. *Brain Res.* 2010;1362:13-22.

155. Kester M, Teunissen CE, Crimmins DL, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic loss in symptomatic Alzheimer Disease. *JAMA Neurol.* 2015:1-7.

156. Zetterberg H, Skillback T, Mattsson N, et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. *JAMA Neurol.* 2016;73(1):60-67.

157. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *The Lancet Neurology.* 2007;6(4):305-313.

158. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. *J Nucl Med.* 2009;50(10):1638-1645.

159. Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid-beta. *Alzheimers Dement.* 2017.

160. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology.* 2010;74(3):201-209.

161. Knopman DS, Penman AD, Catellier DJ, et al. Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. *Neurology.* 2011;76(22):1879-1885.

162. Lopez OL, Klunk WE, Mathis C, et al. Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. *Neurology.* 2014;83(20):1804-1811.

163. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update: Mild cognitive impairment Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* In Press 2017.

164. Association AP, Force APAD-T. Diagnostic and statistical manual of mental disorders: DSM-5. 2013:xliiv, 947 p.

165. Reed BR, Mungas D, Farias ST, et al. Measuring cognitive reserve based on the decomposition of episodic memory variance. *Brain.* 2010;133(Pt 8):2196-2209.

166. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. *Ann Neurol.* 2007;63(3):353-364.

167. Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. *Ann Neurol.* 2012;72(5):730-738.

168. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology.* 2007;69(24):2197-2204.

169. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. *Ann Neurol.* 2009;66(2):200-208.

170. Sonnen JA, Santa Cruz K, Hemmy LS, et al. Ecology of the aging human brain. *Arch Neurol.* 2011;68(8):1049-1056.

171. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. *The American journal of psychiatry.* 1982;139(9):1136-1139.
172. Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. *Alzheimers Dement.* 2016;12(2):195-202.

173. Fischer CE, Qian W, Schweizer TA, et al. Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer’s disease. *Alzheimer’s & Dementia: Translational Research & Clinical Interventions.* 2017;3(3):385-392.

174. Maass A, Landau S, Baker S, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s Disease. *Neuroimage.* In Press 2017.

175. Lockhart SN, Scholl M, Baker SL, et al. Amyloid and tau PET demonstrate region-specific associations in normal older people. *Neuroimage.* 2017;150:191-199.

176. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. *Alzheimer’s & dementia.* 2015;11(1):1-15.

177. Frisoni GB, Jack CR, Jr., Bocchetta M, et al. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. *Alzheimers Dement.* 2015;11(2):111-125.

178. Carrillo MC, Blennow K, Soares H, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. *Alzheimers Dement.* 2013;9(2):137-140.

179. Kuhlmann J, Andreasson U, Pannee J, et al. CSF Abeta1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. *Clin Chim Acta.* 2017;467:27-33.

180. Mormino EC, Brandel MG, Madison CM, et al. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. *Neuroimage.* 2012;59(2):1152-1160.

181. Villeneuve S, Rabinovici GD, Cohn-Sheehy Bl, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. *Brain.* 2015;138(Pt 7):2020-2033.

182. Nelson PT, Jicha GA, Schmitt FA, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. *J Neuropathol Exp Neurol.* 2007;66(12):1136-1146.

183. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. *Ann Neurol.* 2008;64(2):168-176.

184. Au R, Seshadri S, Knox K, et al. The Framingham Brain Donination Program: neuropathology along the cognitive continuum. *Curr Alzheimer Res.* 2012;9(6):673-686.

185. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *J Neuropathol Exp Neurol.* 2011;70(11):960-969.

186. Jack CR, Jr., Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. *The Lancet Neurology.* 2014;13(10):997-1005.

187. Smith EE, Saposnik G, Biessels GJ, et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke: a journal of cerebral circulation.* 2017;48(2):e44-e71.

188. Gupta A, Giambraone AE, Gialdini G, et al. Silent Brain Infarction and Risk of Future Stroke: A Systematic Review and Meta-Analysis. *Stroke: a journal of cerebral circulation.* 2016;47(3):719-725.
189. Vermeer SE, Longstreth WT, Jr., Koudstaal PJ. Silent brain infarcts: a systematic review. *The Lancet Neurology*. 2007;6(7):611-619.

190. Ighodaro ET, Nelson PT, Kukull WA, et al. Challenges and Considerations Related to Studying Dementia in Blacks/African Americans. *J Alzheimers Dis*. 2017;60(1):1-10.

191. Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. *Alzheimer's & dementia*. 2016;3:98-102.

192. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol*. 2017;74(5):557-566.

193. Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimers Dement*. 2017;Epub ahead of print.

194. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S1-45.
Table 1 - ATN biomarker grouping

(A) Aggregated β-amyloid or associated pathologic state
   CSF Ab 42, or 42/40 ratio
   Amyloid PET

(T) Aggregated tau (neurofibrillary tangles) or associated pathologic state
   CSF phosphorylated tau
   Tau PET

(N) Neurodegeneration or neuronal injury
   Anatomic MRI
   FDG PET
   CSF total tau
Table 2 – Biomarker profiles and categories

| ATN profiles | Biomarker category                  |
|--------------|------------------------------------|
| A-T-N-       | Normal AD biomarkers               |
| A+T-N-       | Alzheimer’s pathologic change      |
| A+T-N+       | Alzheimer’s pathologic change      |
| A+T+N-       | Alzheimer’s disease                |
| A+T+N+       | Alzheimer’s disease                |
| A-T+N-       | Non- AD pathologic change          |
| A-T-N+       | Non- AD pathologic change          |
| A-T+N+       | Non- AD pathologic change          |

Binarizing the 3 ATN biomarker types leads to 8 different biomarker “profiles”. Every individual can be placed into one of 3 general biomarker “categories” based on biomarker profiles: those with normal AD biomarkers (no color), those with non-AD pathologic change (dark grey), and those who are in the Alzheimer’s continuum (light grey). The term “Alzheimer’s continuum” is an umbrella term that denotes either Alzheimer’s pathologic change or AD.

*If an individual has an abnormal amyloid biomarker study, but a biomarker for tau is not available, then the individual is placed into the “Alzheimer’s continuum”
Table 3 – Syndromal staging of cognitive continuum: applicable to all members of a research cohort independent from biomarker profiles

Cognitively Unimpaired

Cognitive performance within expected range for that individual based on all available information. This may be based on clinical judgment and/or on cognitive test performance (which may or may not be based on comparison to normative data with or without adjustments for age, education, occupation, sex, etc.).

Cognitive performance may be in the impaired/abnormal range based on population norms but performance is within the range expected for that individual.

A subset of cognitively unimpaired individuals may report subjective cognitive decline and/or demonstrate subtle decline on serial cognitive testing.

Mild cognitive Impairment

Cognitive performance below expected range for that individual based on all available information. This may be based on clinical judgment and/or on cognitive test performance (which may or may not be based on comparison to normative data with or without adjustments for age, education, occupation, sex, etc.).

Cognitive performance is usually in the impaired/abnormal range based on population norms but this is not required as long as performance is below the range expected for that individual.

In addition to evidence of cognitive impairment, evidence of decline in cognitive performance from baseline must also be present. This may be reported by the individual or by an observer (e.g., study partner) or observed by change on longitudinal cognitive testing/behavioral assessments or by a combination of these.

May be characterized by cognitive presentations that are not primarily amnestic*

Although cognitive impairment is the core clinical criteria, neurobehavioral disturbance may be a prominent feature of the clinical presentation**

Performs daily life activities independently but cognitive difficulty may result in detectable but mild functional impact on the more complex activities of daily life, either self-reported or corroborated by study partner.
Dementia

Substantial progressive cognitive impairment that affects several domains and/or neurobehavioral symptoms. May be reported by the individual or by an observer (e.g. study partner) or observed by change on longitudinal cognitive testing

Cognitive impairment and/or neurobehavioral symptoms result in clearly evident functional impact on daily life. No longer fully independent/requires assistance with daily life activities. This is the primary feature differentiating dementia from MCI.

May be subdivided into mild, moderate and severe

* For MCI and dementia: Cognitive impairment may be characterized by presentations that are not primarily amnestic

**For MCI and dementia: Although cognition is the core feature, neurobehavioral changes - e.g. changes in mood, anxiety, or motivation – commonly co-exist and may be a prominent part of the presentation.
**Table 4. Descriptive nomenclature: syndromal cognitive staging combined with biomarkers**

| Biomarker Profile | Cognitively Unimpaired                                                                 | Mild Cognitive Impairment                                      | Dementia                                      |
|-------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------|
| A⁻ T⁺ N⁻          | normal AD biomarkers, cognitively unimpaired                                           | normal AD biomarkers with MCI                                 | normal AD biomarkers with dementia            |
| A⁺ T⁺ N⁻          | Preclinical Alzheimer’s pathologic change                                             | Alzheimer’s pathologic change with MCI                       | Alzheimer’s pathologic change with dementia   |
| A⁺ T⁺ N⁺          | Preclinical Alzheimer’s disease                                                        | Alzheimer’s disease with MCI(Prodromal AD)                    | Alzheimer’s disease with dementia             |
| A⁺ T⁺ N⁺          | Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change, cognitively unimpaired | Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change with MCI | Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change with dementia |
| A⁻ T⁺ N⁺          | non-Alzheimer’s pathologic change, cognitively unimpaired                              | non-Alzheimer’s pathologic change with MCI                   | non-Alzheimer’s pathologic change with dementia |
| A⁻ T⁻ N⁺          |                                                                                       |                                                              |                                               |
Table 5. Risk of short term cognitive decline based on biomarker profile and cognitive stage

| Biomarker Profile | Syndromal Cognitive Stage | Cognitively unimpaired | MCI | dementia |
|-------------------|---------------------------|------------------------|-----|----------|
| A⁻ T⁻ N⁻          | normal AD biomarkers, cognitively unimpaired | normal AD biomarkers with MCI | normal AD biomarkers with dementia |
| A⁺ T⁻ N⁻          | Preclinical Alzheimer’s pathologic change | Alzheimer’s pathologic change with MCI | Alzheimer’s pathologic change with dementia |
| A⁺ T⁺ N⁻          | Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change, cognitively unimpaired | Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change with MCI | Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change with dementia |
| A⁺ T⁻ N⁺          | Preclinical Alzheimer’s disease | Alzheimer’s disease with MCI (Prodromal AD) | Alzheimer’s disease with dementia |
| A⁺ T⁺ N⁺          | Alzheimer’s disease | Alzheimer’s disease with dementia |

Non-Alzheimer’s continuum profiles are not included in table because the risk associated with different combinations of T+N⁻, T+N⁺, T⁻N⁺ among A⁻ individuals has not been established

- [ ] rate of short term clinical progression expected to be low
- [ ] rate of short term clinical progression expected to be high
Table 6: Numeric clinical staging - applicable only to individuals in the Alzheimer’s pathologic continuum

Stage 1

Performance within expected range on objective cognitive tests. Cognitive test performance may be compared to normative data of the investigators choice, with or without adjustment (again the choice of the investigators) for age, sex, education, etc.*

Does not report recent decline in cognition or new onset of neurobehavioral symptoms of concern

No evidence of recent cognitive decline or new neurobehavioral symptoms by report of an observer (e.g. study partner) or by longitudinal cognitive testing if available

Stage 2

Normal performance within expected range on objective cognitive tests.

 Transitional cognitive decline: decline in previous level of cognitive function which may involve any cognitive domain(s) (i.e. not exclusively memory).

   May be documented through subjective report of cognitive decline that is of concern to the participant
   
   Represents a change from individual baseline within past 1-3 years, and persistent for at least 6 months
   
   May be corroborated by informant but not required

   OR may be documented by evidence of subtle decline on longitudinal cognitive testing but not required

   Or may be documented by both subjective report of decline as well as objective evidence on longitudinal testing

Although cognition is the core feature, mild neurobehavioral changes - e.g. changes in mood, anxiety, or motivation – may co-exist. In some individuals the primary compliant may be neurobehavioral rather than cognitive. Neurobehavioral symptoms should have a clearly defined recent onset which persists and cannot be explained by life events. **

No functional impact on daily life activities
Stage 3

Performance in the impaired/abnormal range on objective cognitive tests.

Evidence of decline from baseline, documented by the individual’s report or by observer (e.g. study partner) report or by change on longitudinal cognitive testing or neurobehavioral behavioral assessments.

May be characterized by cognitive presentations that are not primarily amnestic***

Performs daily life activities independently but cognitive difficulty may result in detectable but mild functional impact on the more complex activities of daily life, i.e., may take more time or be less efficient but still can complete, either self-reported or corroborated by study partner.

Stage 4

Mild dementia

Substantial progressive cognitive impairment affecting several domains, and/or neurobehavioral disturbance. Documented by the individual’s report or by observer (e.g. study partner) report or by change on longitudinal cognitive testing.

Clearly evident functional impact on daily life, affecting mainly instrumental activities. No longer fully independent/requires occasional assistance with daily life activities.

Stage 5

Moderate dementia

Progressive cognitive impairment or neurobehavioral changes Extensive functional impact on daily life with impairment in basic activities. No longer independent and requires frequent assistance with daily life activities.

Stage 6

Severe dementia

Progressive cognitive impairment or neurobehavioral changes. Clinical interview may not be possible.
Complete dependency due to severe functional impact on daily life with impairment in basic activities, including basic self-care.

* For stages 1-6: Cognitive test performance may be compared to normative data of the investigators choice, with or without adjustment (choice of the investigators) for age, sex, education, etc.

**For stages 2-6: Although cognition is the core feature, neurobehavioral changes - e.g. changes in mood, anxiety, or motivation – may co-exist.

***For stages 3-6: Cognitive impairment may be characterized by presentations that are not primarily amnestic
Fig 1. Alzheimer’s disease with dementia. 75 yo woman with amnestic multi domain dementia, abnormal amyloid PET (a), tau PET (b,c) and atrophy on MRI (d). Biomarker profile A+T+N+. 
**Fig 2. Preclinical Alzheimer’s pathologic change.** Cognitively unimpaired 67 yo man. Abnormal amyloid PET (top row), no uptake on tau PET (middle row), no atrophy on MR (bottom row). Biomarker profile A+T-N-.
Fig 3. Alzheimer’s and concomitant suspected non Alzheimer’s pathologic change with dementia. 91 yo, M, severe amnestic dementia, abnormal amyloid PET (a,b), normal tau PET 9 (c,d) and severe medial temporal atrophy on MRI (e,f). The biomarker profile (A+ T- N+) suggests the patient has Alzheimer’s pathologic change (A+T-) plus an additional degenerative condition (N+), likely hippocampal sclerosis.